Key StatisticsCurrency:USD
EPS(TTM)
-1.22
P/E(TTM)
-0.33
BVPS
0.33
P/B
0.93
Revenue(2024 Q4)
--
YoY
--
Net Income(2024 Q4)
-2.36M
YoY
70.11%
Gross Margin(TTM)
--
Net Margin(TTM)
--
ROE(TTM)
--
Debt ratio
38.46%
Dividend Yield(TTM)
--
Payout Ratio
--
Unveiling the company's Dividend Strategy
Profile
Cellectar Biosciences, Inc.
A late-stage biopharmaceutical company focused on targeted treatments for cancer
Related Sections
- Pharmaceuticals+0.62%
Pharma Tracker
No Upcoming Event
Stay ahead with our Pharma Tracker: Monitor the latest developments in new drug research, financial health, and FDA updates for the company
Revenue BreakdownCurrency:USD
Business
Region
No Data
Major shareholders
Entities Affiliated with Rosalind Advisors, Inc.
DividendsCurrency:USD
No Data
Net Income Attributable to Parent
Total Cash Dividends
Payout Ratio
Unveiling the company's Dividend Strategy
Institutional Holdings
Totally
29
institutions reported their ownerships on CLRB
Institutional Holding Ratio
Price
Insider Transactions
Net increase
Net decrease
Price
Stock split and consolidation
Declaration Date
Plan
Ex-Div Date
Jul 22, 2022
10->1
Jul 22, 2022
Executive Profile
Executives
Board
J
James Caruso
President, Chief Executive Officer and Director
D
Dov Elefant
Vice President and Chief Financial Officer
J
Jarrod Longcor
Chief Business Officer
J
John E. Friend II
Vice President and Chief Medical Officer
(CLRB)
------
As of 16:25 EST Sun 03/16/2025Disclaimer: All data and information presented above are from third-party data sources. They are for reference only and do not constitute any investment advice.
Market Data Risk Disclosure|Privacy Policy
